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Introduction
Among the countries of Europe, Ukraine has the highest preva-
lence of adult infection with human immunodeficiency virus 
(HIV) (1.6%) and the highest rate of mortality attributable to 
acquired immunodeficiency syndrome (AIDS) (8.2 deaths per 
100 000 population in 2011).1–3 The country’s epidemic of HIV 
infection has been driven by the practice of injecting illicit 
drugs.1 The quality of HIV care provided in Ukraine has been 
badly affected by the severe economic crisis that followed the 
country’s independence in 1991 and by the limitations of its 
verticalized health-care system.4 Although the national scale-
up of antiretroviral therapy (ART) began in 2004, need has 
outstripped supply and the devolution of budgets has led to 
regional disparities in access to such therapy.4,5 In 2011, 30% 
of individuals who were eligible for ART and in HIV care in 
Ukraine were not receiving ART, and 13% of those on ART 
were having their therapy financed by the Global Fund to Fight 
AIDS, Tuberculosis and Malaria.1 In the same year, the ART 
regimens in common use in Ukraine cost at least 100 United 
States dollars per patient.6
The elimination of new HIV infections in infants by 2015 
is a current global target,7 and the prevention of mother-to-
child transmission (PMTCT) of HIV has become a public-
health priority in many countries, including Ukraine.1 In 2010, 
the World Health Organization (WHO) published guidelines 
for the use of ART in pregnant women.8 These guidelines 
recommended initiation of lifelong combination ART (cART) 
for all pregnant women with CD4+ T-lymphocyte (CD4+ 
cell) counts of ≤ 350 per µl and/or HIV disease in WHO 
stage 3 or 4. They also recommended two options for those 
pregnant women who require ART for PMTCT only: Op-
tion A, consisting of zidovudine monotherapy (AZTm) plus 
single-dose nevirapine (sdNVP), and Option B, consisting of 
antenatal cART.8 In 2012, WHO published a programmatic 
update on “Option B+” – the initiation of lifelong cART for 
all HIV-positive pregnant women.9 The potential benefits 
of this approach include improved maternal health and the 
harmonization of treatment programmes.10
Following the scale-up of PMTCT services in Ukraine, the 
rate of MTCT fell from 15% in 2001 to 6–7% in 2007, although 
the annual numbers of new infections in women of childbear-
ing age – many of which had been acquired heterosexually –in-
creased over the same period.1,3,11–13 By 2011, the prevalence of 
HIV infection among pregnant women was higher in Ukraine 
(0.47%) than in any other country in Europe1 and exceeded 3% 
in some regions of the country (personal communication, Na-
talya Nizova, 2012). In 2007, 92% of the HIV-positive pregnant 
women in Ukraine received ART, and PMTCT prophylaxis 
was based on AZTm and sdNVP.13,14 In November 2007, the 
country’s Ministry of Health recommended the national 
implementation of WHO’s Option-B strategy. The present 
study was based on data collected in Ukraine between 2008 
and 2010 as part of a larger, prospective, observational study 
of HIV-positive pregnant women and their infants. The aims 
of the present study were to investigate coverage with antenatal 
cART, the factors associated with receipt of AZTm – rather 
than cART – and MTCT rates.
Objective To investigate the scale-up of antenatal combination antiretroviral therapy (cART) in Ukraine since this became part of the national 
policy for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV).
Methods Data on 3535 HIV-positive pregnant women who were enrolled into the Ukraine European Collaborative Study in 2008–2010 
were analysed. Factors associated with receipt of zidovudine monotherapy (AZTm) – rather than cART – and rates of mother-to-child 
transmission (MTCT) of HIV were investigated.
Findings cART coverage increased significantly, from 22% of deliveries in 2008 to 61% of those in 2010. After adjusting for possible 
confounders, initiation of antenatal AZTm – rather than cART – was associated with cohabiting (versus being married; adjusted prevalence 
ratio, aPR: 1.09; 95% confidence interval, CI: 1.02–1.16), at least two previous live births (versus none; aPR: 1.22; 95% CI: 1.11–1.35) and a 
diagnosis of HIV infection during the first or second trimester (versus before pregnancy; aPR: 1.11; 95% CI: 1.03–1.20). The overall MTCT rate 
was 4.1% (95% CI: 3.4–4.9); 42% (49/116) of the transmissions were from the 8% (n = 238) of women without antenatal ART. Compared with 
AZTm, cART was associated with a 70% greater reduction in the risk of MTCT (adjusted odds ratio: 0.30; 95% CI: 0.16–0.56).
Conclusion Between 2008 and 2010, access to antenatal cART improved substantially in Ukraine, but implementation of the World Health 
Organization’s Option-B policy was slow. For MTCT to be eliminated in Ukraine, improvements in the retention of women in HIV care and 
further roll-out of Option B are urgently needed.
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Methods
The European Collaborative Study is 
an ongoing, observational, birth cohort 
study in which HIV-positive pregnant 
women – diagnosed before or during 
pregnancy or around the time of de-
livery – are enrolled and their infants 
are prospectively followed, either for 
18–24 months if HIV-negative or on 
an ongoing basis if HIV-positive.13 
Data collection takes place at delivery 
and then as often as infant follow-up 
allows. The study began enrolment in 
Ukraine in 2000 and seven Ukrainian 
centres for HIV care currently partici-
pate. Informed consent is obtained for 
collection of linked anonymous data 
on maternal, infant and delivery char-
acteristics and clinical parameters.13 
The study protocol was approved by 
the Great Ormond Street Hospital for 
Children NHS Trust/Institute of Child 
Health Research Ethics Committee and 
by local institutional review boards.
For the present data analyses, 54 
infants who were products of multiple 
pregnancies but were not the firstborn 
infant of the multiple birth were ex-
cluded from the study (Fig. 1) except 
in two cases of discordant infection 
status, in which the infected infant 
was retained instead of the uninfected 
firstborn infant.
Definitions
All 3535 infants included in the present 
study were 7 months of age or older at 
the time of data analysis. Most (69%) 
of these infants had been tested for 
HIV deoxyribonucleic acid (DNA) by 
polymerase chain reaction at least once 
by the time of the data analysis. Infants 
found positive using this assay were 
considered HIV-positive, regardless of 
age, as were infants with persistence of 
anti-HIV antibodies beyond 18 months 
of age. Infants who were negative for 
HIV DNA (except at birth) and/or 
negative for anti-HIV antibodies were 
classified as HIV-negative, regardless of 
age. Infants with conflicting results were 
classified as “indeterminate”. A viral 
load of ≤ 75 copies of ribonucleic acid 
(RNA) per ml – the detection limit of the 
RealTime assays (Abbott Laboratories, 
Abbott Park, United States of America) 
used – was defined as “undetectable”. 
cART was defined as three or more 
antiretroviral drugs taken simultane-
ously. Twenty of the pregnant women 
included in the data analysis received 
two antiretroviral drugs – rather than 
a full cART regimen – because of drug 
shortages (personal communication, 
Igor Semenenko, 2012); these women 
were assigned to the AZTm group. ART 
given to pregnant women before labour 
was categorized as “antenatal ART”, 
whereas ART given during labour and/
or delivery was categorized as “intrapar-
tum ART”. History of injecting drug use 
was determined by self-report, clinical 
assessment and/or the development of 
abstinence syndrome in the neonate. 
Pregnant women with CD4+ cell counts 
of ≤ 350 per µl and/or HIV disease in 
WHO stage 3 or 4 were considered 
eligible for ART.15
Data analysis
The χ2 test for categorical variables, 
the Wilcoxon Mann–Whitney test or 
the Kruskal–Wallis test were used in 
univariable comparisons. In analyses 
exploring factors associated with the 
initiation of AZTm rather than cART 
during pregnancy, Poisson regression 
models – with robust variance estima-
tors to control for underdispersion16 
– were used to obtain prevalence ratios 
(PRs), adjusted prevalence ratios (aPRs) 
and 95% confidence intervals (CIs). 
Odds ratios (ORs) were avoided because 
they are more difficult to interpret than 
PRs when outcomes are common.16 
Fig. 1. Study enrolment, showing the antenatal and intrapartum antiretroviral therapy 
(ART) received, Ukraine, 2008–2010
54 infants from multiple births 
excluded (52 twins and 2 of a 
set of triplets)
228 pregnancies with no 
WHO stage or antenatal 
CD4+ cell count available
1966 not eligible for ART
required ART for prophylaxis
3535 pregnancies with
information on antenatal
ART receipt
3615 mother–infant
pairs 2008–2010
3068 pregnancies with 
ART initiated antenatally
191 received
AZTm
683 received 
cART
1233 received
AZTm
733 received
cART
26 pairs missing information on ART
131 conceptions on cART
874 eligible for ART
336 pregnancies with no antenatal ART
cART, combination antiretroviral therapy; CD4+ cell, CD4+ T-lymphocyte; WHO, World Health 
Organization; AZTm, zidovudine monotherapy.
Note: The pregnant women who received no antenatal ART were diagnosed as HIV-positive before 
conception (n = 120), during pregnancy (n = 69), intrapartum (n = 48) or at an unrecorded time (n = 99). 
The denominator used for pregnancies with no antenatal ART or timing of diagnosis available was 
therefore 237. The women who were eligible for ART were considered eligible because they had HIV 
disease in WHO stage 3 or 4 (n = 311), ≤ 350 CD4+ cells per µl (n = 707) or both (n = 144). The women 
who were not eligible for ART had HIV disease in WHO stage 1 or 2 and no data on their CD4+ cells 
(n = 665) or > 350 CD4+ cells per µl and either no information on their WHO stage (n = 110) or HIV 
disease in stage 1 or 2 (n = 1191). In 24% (317/1301) of pregnancies, a CD4+ cell count of > 350 per 
µl was taken after ART initiation. These 317 pregnancies were included among the 1966 that were 
categorized as “not eligible for ART; required ART for prophylaxis”.
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These analyses were limited to the 2840 
pregnancies for which data on WHO 
stage and/or antenatal CD4+ cell counts 
were available, which represented 93% 
of the 3068 pregnancies in which ART 
was initiated antenatally (Fig. 1). The 
contribution that each factor made to a 
model’s goodness-of-fit was investigated 
using the Wald test; a covariate was in-
cluded if it gave a P-value of < 0.1.
Logistic regression models were 
fitted to calculate ORs, adjusted ORs 
(aORs) and 95% CIs for factors asso-
ciated with MTCT. All except one of 
the factors previously associated with 
MTCT risk in this cohort (i.e. type of 
antenatal/intrapartum ART, mode of 
delivery, preterm delivery and history 
of injecting drug use)13 were included a 
priori. The exception was breastfeeding, 
which was excluded because very few of 
the women included in the data analysis 
breastfed their infants. Inclusion of ma-
ternal WHO stage and CD4+ cell count 
depended on these variables showing 
a level of significance of P-value < 0.1 
in likelihood ratio tests. The effects on 
MTCT of antenatal ART duration and 
antenatal viral load – available for 54% 
of the 2854 infants with known infec-
tion status reported – were explored in 
subanalyses.
All models were adjusted a priori 
for year and HIV centre of enrolment; 
the latter variable was included as a 
random effect in the logistic regres-
sion models17 and as a covariate in the 
Poisson regression models. Maternal 
educational status, which was only avail-
able for 44% (n = 1545) of the women in-
cluded in the data analysis, was excluded 
from the main multivariable models to 
avoid bias.
All of the statistical analyses were 
performed using Stata version 11.0 
(StataCorp. LP, College Station, USA).
Results
Antenatal cART was received by 45% 
(1606) of the 3535 pregnant women 
overall. Coverage of cART increased 
significantly over the study period, from 
22% (270) of the 1217 pregnant women 
who delivered in 2008 to 61% (627) of 
the 1027 who delivered in 2010 (P for 
trend: 0.03). Overall 45% (1593/3535) of 
women received AZTm, with or without 
sdNVP; 5% (163/3535) received sd-
NVP alone and another 5% (173/3535) 
received no antenatal or intrapartum 
ART. Of the 3429 women with the date 
of HIV diagnosis available, 38% (1315) 
were diagnosed as HIV-positive before 
their current pregnancy and 131 (10%) 
of these women had conceived while 
on cART. Of 841 women who were 
diagnosed as HIV-positive before their 
current pregnancy and had their CD4+ 
cell count determined during pregnancy, 
335 (40%) had a count of ≤ 350 cells per 
µl. Of the 336 HIV-positive pregnant 
women who received no antenatal ART, 
237 had the dates of their HIV diagnosis 
recorded. Of these, 189 (80%) were di-
agnosed as HIV-positive before delivery 
and 120 (51%) had been diagnosed as 
HIV-positive before they had conceived.
Maternal and delivery character-
istics are shown, according to the ART 
received, in Table 1. Most of the women 
were either married or cohabiting and 
15% (514/3505) had been or were in-
jecting drug users. Of the 1606 women 
who received cART, 91% (1458) received 
a regimen that was protease-inhibitor-
based – predominantly a combination of 
zidovudine, lamivudine and lopinavir/
ritonavir. Overall, 96% (3236/3388) of 
infants received neonatal prophylaxis. 
Of the 2872 infants who received neo-
natal prophylaxis of known type, 85% 
(2443) received zidovudine for 7 days, 
with or without sdNVP.
The results of at least one antenatal 
CD4+ cell count were available for 64% 
(2264/3535) of the women. This propor-
tion increased from 50% (606/1217) 
of the women who delivered in 2008 
to 73% (749/1027) of the women who 
delivered in 2010. For 2213 women with 
both the date of their first CD4+ cell 
count in pregnancy and date of ART 
initiation available, 67% (1493) had had 
their CD4+ cell count measured before 
they initiated ART. Of the 2264 first an-
tenatal cell counts recorded, 34% (774) 
and 11% (249) were ≤ 350 and ≤ 200 
CD4+ cells per µl, respectively. Overall, 
of the 2990 women who had the WHO 
stage of their HIV disease recorded, 14% 
(411) had stage 3 or stage 4 disease. Of 
the 3182 pregnancies for which CD4+ 
cell counts and/or WHO stage were re-
corded, 32% (1009) were in ART-eligible 
women. For 59% (598) of these women, 
ART eligibility was identified only by 
CD4+ cell count. Of the women who 
were ART-eligible and initiated ART 
during pregnancy, cART was received 
by 56% (137/244), 83% (276/332) and 
91% (270/298) of those delivering in 
2008, 2009 and 2010, respectively (P for 
trend: < 0.01).
Among the women with data avail-
able on WHO stage and/or CD4+ 
cell counts who initiated ART for 
PMTCT only, cART was received by 
12% (84/709), 49% (360/731) and 55% 
(289/526) of those delivering in 2008, 
2009 and 2010, respectively (P for trend: 
< 0.01). In general, women initiating 
AZTm had higher CD4+ cell counts than 
those initiating cART (Table 1; P < 0.01). 
Only 68% (239) of the 353 women with-
out a recorded WHO stage or CD4+ cell 
count received antenatal ART, compared 
with 93% (2960) of the other 3182 
women (χ2 = 236.79; P < 0.01). Women 
without a recorded WHO stage or CD4+ 
cell count were also more likely to have 
had their HIV infection diagnosed 
in the third trimester or intrapartum 
[16% (51/318) versus 11% (331/3111) 
of the women with one or both mea-
sures; χ2 = 8.49; P < 0.01]. Women with 
histories of injecting drug use were less 
likely to receive antenatal ART than the 
other women [82% (419/514) versus 
93% (2769/2991); χ2 = 65.23; P < 0.01].
Factors associated with receipt of 
antenatal AZTm
The proportion of women initiating 
AZTm (rather than cART) during preg-
nancy varied significantly by HIV centre 
(data not shown; χ2 = 232.70; P < 0.01). 
Overall, almost two thirds of the women 
who did not require treatment for their 
own health – but only 22% of the ART-
eligible women – initiated AZTm rather 
than cART (Table 2). In addition to year 
of delivery, HIV centre and ART eligibil-
ity, other factors that were found to be 
associated with initiation of AZTm in 
univariable analyses included a history 
of injecting drug use in the woman or 
her partner, marital status, previous live 
births, timing of HIV diagnosis and edu-
cational status (Table 2). For the women 
who delivered in 2010 and who initiated 
ART during pregnancy, the probability 
of receiving antenatal AZTm was less 
than half the probability among women 
who delivered in 2008, after adjusting for 
other factors (Table 2). In the adjusted 
models, having had at least two previous 
live births (versus none) and cohabiting 
(versus married) were both associated 
with an increased likelihood of receiv-
ing AZTm. Women diagnosed as HIV-
positive during pregnancy were also 
more likely to receive AZTm than those 
diagnosed before conception, partly 
because they were less likely to be ART-
eligible [27% (500/1847) eligible versus 
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38% (374/987); χ2 = 35.32; P < 0.01]. 
This association remained significant 
after adjusting for treatment eligibility 
and other factors (Table 2). Among the 
ART-naive women, those who had been 
or were injecting drug users were more 
likely to be ART-eligible than the other 
women [41% (148/358) versus 29% 
(720/2471); χ2 = 21.89; P < 0.01]. In the 
adjusted models, a history of injecting 
drug use was not significantly associated 
with receipt of AZTm.
In a multivariable model that in-
cluded adjustment for educational status 
when known – in addition to the other 
factors in Table 2 (n = 1555) – women 
who had left full-time education when 
they were younger than 16 years or 
17–18 years of age were found to have 
been more likely to receive AZTm than 
the women who had stayed in full-time 
education until they were 19 or older, 
with an aPR (and 95% CI) of 1.43 (1.25–
1.64) and 1.18 (1.05–1.33), respectively. 
Table 1. Maternal and infant characteristics, Ukraine, 2008–2010
Characteristica Conceived while on 
cART (n = 131)
ART initiated during pregnancy or received at delivery
cART (n = 1475) AZTm, with or with-
out sdNVP (n = 1593)
sdNVP only or no ART 
(n = 336)
Maternal age (years) (n = 3523), median (IQR) 30.0 (27.2–32.6) 27.3 (23.7–31.1) 26.1 (22.9–30.0) 27.5 (24.0–32.0)
Marital status (n = 3523), No. (%)
Married 81 (62) 698 (47) 694 (44) 90 (27)
Cohabiting 43 (33) 561 (38) 653 (41) 147 (45)
Single 7 (5) 211 (14) 246 (15) 92 (28)
Previous live births at enrolment (n = 3463),  
No. (%)
No 34 (27) 781 (54) 907 (57) 118 (37)
Yes 95 (74) 654 (46) 676 (43) 198 (63)
Timing of HIV diagnosis (n = 3428), No. (%)
Before pregnancy 131 (100) 588 (40) 476 (30) 120 (51)
First or second trimester 0 749 (51) 950 (60) 33 (14)
Third trimester 0 135 (9) 163 (10) 36 (15)
Delivery 0 0 0 48 (20)
Age at leaving full-time education (years) 
(n = 1990), No. (%)
≤ 16 14 (19) 104 (13) 180 (20) 41 (23)
17–18 24 (32) 253 (31) 255 (28) 82 (46)
≥ 19 37 (49) 463 (56) 481 (53) 56 (31)
History of IDU (n = 3505), No. (%)
No 86 (66) 1251 (85) 1431 (90) 222 (70)
Yes 44 (34) 217 (15) 158 (10) 95 (30)
Partner with history of IDU (n = 3440), No. (%)
No 89 (68) 1016 (71) 1208 (77) 245 (81)
Yes 42 (32) 415 (29) 366 (23) 59 (19)
Maternal WHO stage (HIV disease severity),  
No. (%) (n = 2 990)
1 or 2 (asymptomatic/mild) 45 (39) 1096 (82) 1251 (95) 187 (86)
3 or 4 (advanced/severe) 70 (61) 240 (18) 71 (5) 30 (14)
CD4+ cell count (n = 2263)b
Cells per µl, median (IQR) 370 (260–490) 360 (250–510) 530 (410–660) 410 (295–530)
≤ 350 cells per µl, no. (%) 49 (48) 577 (48) 130 (14) 18 (45)
Mode of delivery (n = 3533), No. (%)
Vaginal/emergency CS 77 (59) 1021 (69) 1130 (71) 311 (93)
Elective CS 54 (41) 454 (31) 461 (29) 25 (7)
Gestation at delivery (weeks) (n = 3520), No. (%)
≥ 37 113 (86) 1336 (91) 1482 (94) 267 (81)
< 37 18 (14) 137 (9) 103 (6) 64 (19)
MTCT rate (n = 2854),c % (95% CI) 0 (0–3.5) 1.4 (0.8–2.2) 3.8 (2.8–5.0) 20.6 (15.6–26.3)
ART, antiretroviral therapy; AZTm, zidovudine monotherapy; cART, combination antiretroviral therapy; CD4+ cell, CD4+ T-lymphocyte; CI, confidence interval; CS, 
caesarean section; HIV, human immunodeficiency virus; IDU, injecting drug use; IQR, interquartile range; MTCT, mother-to-child-transmission; sdNVP, single-dose 
nevirapine; WHO, World Health Organization.
a  The n-values indicate the number of women for whom the relevant information was available.
b  Results of the first count in pregnancy, obtained at a median of 23 weeks’ gestation.
c  The values shown are for mother–infant pairs showing transmission.
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Among the women who were ineligible 
for ART, lower educational status was 
also associated with lower CD4+ cell 
counts: the median CD4+ cell counts 
for such women who left full-time edu-
cation when aged 16 or less, 17–18 and 
19 years or older were 510, 530 and 560 
cells per µl, respectively (P = 0.05). After 
adjusting for educational status, the 
associations between AZTm initiation 
and having had at least two previous 
live births or cohabiting were no longer 
statistically significant, with an aPR (and 
95% CI) of 1.14 (1.00–1.30) and 1.06 
(0.97–1.17), respectively.
Mother-to-child transmission
Among the 2854 infants with recorded 
HIV infection status, the overall rate 
of MTCT was 4.1% (95% CI: 3.4–4.9). 
The rate of MTCT was 1.3% (95% CI: 
0.7–2.0) among the women who re-
ceived antenatal cART, 3.8% (95% CI: 
2.8–5.0) among those who received 
AZTm, 18.6% (95% CI: 12.3–26.4) fol-
lowing sdNVP only and 22.9% (95% CI: 
15.4–32.0) among the untreated women. 
Overall, 42% (49) of the 116 transmis-
sions from mothers to infants occurred 
in the 8% of cases (n = 238) in which 
antenatal ART had not been received. 
MTCT occurred among 3.0% (95% CI: 
1.0–6.8) of the 167 ART-eligible women 
who received AZTm compared with 
3.7% (95% CI: 2.7–5.1) of the 1045 ART-
ineligible women who received AZTm.
In the adjusted analysis, the reduc-
tion in MTCT was 70% greater in wom-
en who received antenatal cART than 
in those who received AZTm (Table 3). 
Delivery before 37 completed weeks of 
gestation was associated with a twofold 
increased risk of MTCT, although in 
analyses stratified by ART type this asso-
ciation was only statistically significant 
in the AZTm group (aPR: 3.45; 95% CI: 
1.54–7.73) and not among the women 
who received cART (aPR: 2.32; 95% CI: 
0.50–10.65). Maternal CD4+ cell count 
and WHO stage were not included in the 
final model because they gave P-values 
above 0.1 (0.20 and 0.42, respectively) 
in likelihood ratio tests. 
The median duration of antenatal 
AZTm (12.6 weeks; interquartile range, 
IQR: 9.9–14.9) was shorter than that 
of cART (13.9 weeks; IQR: 10.1–16.6). 
Table 2. Factors associated with receipt of zidovudine monotherapy (AZTm) among women who initiated antiretroviral therapy during 
pregnancy, Ukraine, 2008–2010
Characteristic No. of 
women
No. (%) of women 
receiving AZTm
PR (95% CI)
Crude Adjusteda
Year of delivery 
2008 1082 842 (78) 2.36 (2.14–2.62) 2.32 (2.11–2.55)
2009 1129 469 (42) 1.26 (1.12–1.42) 1.25 (1.12–1.39)
2010 857 282 (33) 1.00 1.00
History of IDU
Yes 375 158 (42) 1.00 1.00
No 2682 1431 (53) 1.27 (1.12–1.43) 1.10 (0.99–1.23)
Partner with history of IDU
Yes 781 366 (47) 1.00
No 2224 1208 (54) 1.16 (1.07–1.26)
Marital status
Married 1392 694 (50) 1.00 1.00
Cohabiting 1214 653 (54) 1.08 (1.00–1.16) 1.09 (1.02–1.16)
Single 457 246 (54) 1.08 (0.98–1.19) 1.01 (0.91–1.11)
ART-eligibleb
Yes 874 191 (22) 1.00 1.00
No 1966 1233 (63) 2.87 (2.52–3.27) 2.53 (2.22–2.87)
Previous live births at enrolment 
0 1688 907 (54) 1.00 1.00
1 976 475 (49) 0.91 (0.84–0.98) 1.01 (0.93–1.08)
≥ 2 354 201 (57) 1.06 (0.96–1.17) 1.22 (1.11–1.35)
Timing of HIV diagnosis
Before conception 1064 476 (45) 1.00 1.00
First or second trimester 1699 950 (56) 1.25 (1.15–1.35) 1.11 (1.03–1.20)
Third trimester 298 163 (55) 1.22 (1.08–1.38) 1.02 (0.91–1.15)
Age at leaving full-time education (years)
≥ 19 944 481 (51) 1.00 ND
17–18 508 255 (50) 0.99 (0.89–1.10) ND
≤ 16 284 180 (63) 1.24 (1.12–1.39) ND
ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, injecting drug use; ND, not determined because of missing data; PR, 
prevalence ratio.
a  Based on observations on the 2770 women for whom data were available on all variables included in the multivariable model, and including a priori adjustments for 
year of delivery and HIV centre of enrolment.
b  Women with antenatal CD4+ T-lymphocyte counts of ≤ 350 cells per µl and/or HIV disease in World Health Organization stage 3 or 4 were considered ART-eligible.
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Among the 2527 women who had re-
ceived ART for at least 14 days by the 
time that they delivered – and after 
adjusting for ART duration (categorized 
as 2–7, 8–11 or ≥ 12 weeks) and the other 
factors given in Table 3 – compared with 
AZTm, cART was associated with a 61% 
greater reduction in the risk of MTCT 
(aOR: 0.39; 95% CI: 0.20–0.74).
Among 1421 women who received 
antenatal ART, each log10 increase in 
antenatal viral load (measured a median 
of 41 days before delivery) was associ-
ated with a 78% increase in transmission 
risk (aOR: 1.78; 95% CI: 1.26–2.53). 
Adjusting for viral load and the other 
factors given in Table 3 had little effect 
on the association seen between MTCT 
risk and cART (aOR: 0.35; 95% CI: 
0.15–0.79).
Infection status was unknown for 
29% (98/336) of the infants born to 
women with no antenatal ART and 
18% (583/3199) of the infants whose 
mothers had received antenatal ART 
(χ2 = 23.41; P < 0.01). When the number 
of HIV infections in these infants was 
estimated – on the assumption that the 
risk of infection for each of these infants 
was the same as for the other infants 
whose mothers had received the same 
treatment, if any – the estimated overall 
rate of MTCT increased from 4.1% to 
4.2% (95% CI: 3.6–4.9).
Discussion
The present study covered three years 
during which cART coverage for HIV-
positive pregnant women was scaled up 
in Ukraine. Over this period, the overall 
rate of MTCT recorded in the study 
cohort was 4.1%. The rate of MTCT 
among women who received cART 
antenatally was 1.3%. This represented 
a 70% reduction in MTCT risk rela-
tive to the reduction observed among 
the women who received AZTm. This 
marked reduction in risk was detected 
even though those women who had the 
more severe HIV disease – who were at 
relatively high risk of transmitting their 
infection – were more likely to receive 
cART than AZTm.18 Although our ob-
servations demonstrate the effectiveness 
of antenatal cART for PMTCT, they 
also indicate that the scale-up in cART 
coverage for pregnant women has been 
a slow process in Ukraine. About 32% 
of the women who delivered in 2010 – 
two years after WHO’s Option B became 
part of Ukraine’s national health policy 
– received AZTm rather than cART dur-
ing their pregnancies.
In Ukraine over the study period, 
ART-eligible women were prioritized 
for receipt of the limited cART supplies, 
as recommended by WHO guidelines.8 
In the present study, 91% of the ART-
eligible women who delivered in 2010 
and initiated ART during pregnancy 
received cART – up from a correspond-
ing value of 56% among the women 
who delivered in 2008. In over half of 
the cases, ART eligibility was identified 
only by low CD4+ cell counts, a fact 
that underscores the importance of such 
counts in assessing ART eligibility.19,20 
Although the probability of a woman 
having her CD4+ cell count measured at 
least once during pregnancy increased 
markedly over the study period, more 
than a quarter of the women who de-
livered in 2010 had no records of CD4+ 
cell counts during pregnancy.
In the adjusted analyses, women 
diagnosed as HIV-positive in the first 
or second trimester were slightly more 
likely to have initiated AZTm than 
those diagnosed as HIV-positive before 
conception. The latter women may have 
had more opportunity to undergo coun-
selling in preparation for initiation of 
Table 3. Factors associated with mother-to-child transmission of human immunodeficiency virus (HIV) within 2854 mother–infant 
pairs, Ukraine, 2008–2010
Characteristic No. of mother–
infant pairs
No. (%) of pairs 
with MTCT
OR (95% CI)
Crude Adjusteda
Antenatal or intrapartum ART
cART 1274 16 (1.3) 0.32 (0.18–0.57) 0.30 (0.16–0.56)
AZTm 1342 51 (3.8) 1.00 1.00
sdNVP only 129 24 (18.6) 5.79 (3.42–9.77) 4.59 (2.51–8.39)
None 109 25 (22.9) 7.53 (4.45–12.76) 4.62 (2.49–8.59)
Mode of delivery
Vaginal 1916 94 (4.9) 1.00 1.00
Elective CS 800 20 (2.5) 0.50 (0.30–0.81) 0.74 (0.43–1.27)
Emergency CS 137 2 (1.5) 0.29 (0.07–1.18) 0.25 (0.06–1.09)
Gestation at delivery (weeks)
≥ 37 2597 92 (3.5) 1.00 1.00
< 37 247 23 (9.3) 2.80 (1.74–4.50) 2.25 (1.29–3.91)
History of IDU
No 2416 92 (3.8) 1.00 1.00
Yes 414 22 (5.3) 1.42 (0.88–2.28) 1.06 (0.60–1.85)
Year of delivery
2008 1102 52 (4.7) 1.00 1.00
2009 1086 23 (2.1) 0.44 (0.27–0.72) 0.50 (0.28–0.89)
2010 666 41 (6.2) 1.32 (0.87–2.02) 1.56 (0.95–2.56)
AZTm, zidovudine monotherapy; ART, antiretroviral therapy; cART, combination antiretroviral therapy; CI, confidence interval; CS, caesarean section; IDU, injecting drug 
use; MTCT, mother-to-child transmission; OR, odds ratio; sdNVP, single-dose nevirapine.
a  Based on observations on the 2819 women for whom data were available on all variables included in the multivariable model. Adjusted odds ratios were estimated 
including a random effect to account for any unobserved variables that were specific to each HIV centre involved.
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cART. Women who had had two or more 
previous live births (versus none) and 
those who were unmarried but in co-
habiting partnerships (versus married) 
were also more likely to have initiated 
AZTm. However, both of these groups 
of women had relatively low educational 
status, which was also associated with an 
increased probability of AZTm receipt – 
even though CD4+ cell counts indicated 
that, in general, the women with low 
educational status were in relatively 
poorer health. In both Switzerland and 
the United States of America, people 
with lower educational attainment or 
socioeconomic status have been found 
to be relatively less likely to initiate 
cART.21,22 However, among treated indi-
viduals, data on the association between 
educational attainment and the progres-
sion of HIV disease are conflicting,21,23 
probably because context-specific 
factors (e.g. adherence support) may 
mitigate the health-related sequelae of 
social deprivation. Ukraine’s verticalized 
system of HIV care, in which most care 
is provided at regional centres, probably 
presents practical and financial barri-
ers to women with childcare respon-
sibilities. Clinicians may be less likely 
to prescribe cART to women attending 
infrequently for care,24,25 particularly 
when supplies of the necessary drugs 
are limited. If access to cART is to be 
made equitable in Ukraine, more work 
is needed to determine the structural 
and individual barriers to HIV care for 
mothers, people with low educational 
status and other groups. Peer support 
and practical assistance with transport 
and childcare costs may help to remove 
some of the barriers.
In the present study, 5% of the 
women received no antenatal or intra-
partum ART. This represents a slight 
improvement on the corresponding 
value (7%) recorded in the same cohort 
study in 2007.13 By using the MTCT 
rates observed among women receiving 
cART and AZTm in the present study, 
it is possible to estimate the overall 
rates of MTCT achievable under differ-
ent scenarios. If all of the women on 
AZTm had received cART instead, the 
predicted overall MTCT rate would have 
been 2.9% (95% CI: 2.3–3.6), compared 
with 2.2% (95% CI: 1.8–2.8) if cART 
coverage had remained unchanged but 
the 336 untreated women had received 
AZTm. In the present study, four in 
every five of the women who received 
no antenatal ART had been diagnosed 
as HIV-positive before delivery and 
50% of them had been diagnosed be-
fore conception. Improvements in the 
retention of women in HIV care after 
HIV diagnosis will therefore be key for 
achieving MTCT rates of < 2%.26–28 Two 
observations made in the present study 
– that over a third of the women who 
had been diagnosed as HIV-positive 
before conception had antenatal CD4+ 
cell counts of ≤ 350 cells per µl and 
that only one in every 10 such women 
conceived while on cART – indicate 
possible disengagement from HIV care 
and a substantial unmet need for HIV 
treatment in Ukraine.1 The expansion 
and maintenance of access to cART for 
people requiring treatment remains a 
priority.1 Postnatally, continuation of 
ART in eligible women is crucial for 
preventing morbidity and mortality 
in the women29 and poor outcomes in 
their HIV-exposed infants,30,31 including 
those associated with maternal illness 
and death.
In the present study, women with 
histories of injecting drug use were 
at increased risk of not receiving any 
antenatal ART, as reported previously 
in Ukraine32 and also in the Russian 
Federation.33 However, such women 
who had initiated ART were no less 
likely to have received cART than the 
women who had no histories of inject-
ing drug use.
A move to Option B+ is not cur-
rently planned in Ukraine, although 
research to explore the feasibility of 
such a move was recently recommended 
following an external evaluation of the 
country’s PMTCT programme (per-
sonal communication, Ruslan Malyuta, 
2012). The present observations, which 
indicate inequitable access to, and slow 
implementation of, Option B in Ukraine, 
should contribute to discussions regard-
ing the future adoption of Option B+ 
in the country, as should the general 
shortfall of ART for eligible individu-
als.1 Some of the advantages offered by 
Option B+ (e.g. the reduction of future 
MTCT risk and the avoidance of re-
peated exposure to short-course ART 
for PMTCT9) may be more apparent in 
areas with higher rates of fertility than in 
Ukraine, where the overall fertility rate 
is just 1.5 children per woman.4 How-
ever, nearly one third of HIV-positive 
childbearing women in Ukraine have 
HIV-negative partners,34 a fact that 
highlights the potential benefit of Op-
tion B+ in preventing onward sexual 
transmissions.35 Questions regarding 
Option B+ – including the risk–benefit 
ratio for the long-term treatment of 
ART-ineligible individuals and how to 
achieve equitable and sustainable ART 
access and improve retention in HIV 
care – are currently being addressed in 
other settings.
The Ukraine European Collab-
orative Study enrols around 30% of the 
HIV-positive women delivering nation-
wide, making its findings broadly gen-
eralizable despite some regional differ-
ences. For the present analyses, we used 
data for the first three complete years 
since the Option B policy was adopted 
in Ukraine. The corresponding data for 
2011–2012 are not yet complete due to 
time lags in reporting, particularly in 
the reporting of infant infection status.
In conclusion, cART access for 
pregnant women in Ukraine improved 
substantially between 2008 and 2010, 
particularly for women eligible for ART, 
although national implementation of the 
Option B policy has been slow. If MTCT 
is to be eliminated by 2015, improve-
ments in access to PMTCT services 
and in the retention of women in HIV 
care are urgently needed in Ukraine, 
alongside further roll-out of Option B. ■
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ملخص
توسيع نطاق الوصول إلى العلاج التوليفي بمضادات الفيروسات القهقرية في الحمل: نتائج مستخلصة من دراسة أترابية في 
أوكرانيا
الغرض  تحري  زيادة  العلاج  التوليفي  بمضادات  الفيروسات 
القهقرية (TRAc) قبل الولادة في أوكرانيا حيث أصبح جزءًا من 
السياسة  الوطنية  لتوقي  انتقال  فيروس  العوز  المناعي  البشري  من 
الأم إلى الطفل (TCTMP).
الطريقة تم تحليل  البيانات  التي تخص  5353 سيدة حامًلا إيجابية 
لفيروس العوز المناعي البشري تم تسجيلهن في الدراسة التعاونية 
الأوروبية  الأوكرانية في  الفترة من  8002  إلى  0102. وتم تحري 
العوامل المرتبطة بتسلم العلاج أحادي الدواء من نوع زيدوفودين 
(mTZA)  –  بدًلا  من  العلاج  التوليفي  بمضادات  الفيروسات 
القهقرية  –  ومعدلات  انتقال  فيروس  العوز  المناعي  البشري  من 
الأم إلى الطفل.
النتائج  ازدادت  تغطية  العلاج  التوليفي  بمضادات  الفيروسات 
القهقرية بشكل كبير، من  22 % من  الولادات في عام  8002 إلى 
16  %  من  الولادات  في  عام  0102.  وبعد  تصحيحه  من  أجل 
العوامل المسببة للالتباس المحتمل، كان بدء العلاج أحادي الدواء 
بالزيدوفودين قبل الولادة – بدًلا من العلاج التوليفي بمضادات 
الفيروسات القهقرية  – مرتبطًا بالمعاشرة (في مقابل الزواج؛ نسبة 
الانتشار  المصححة:  90.1؛  فاصل  الثقة  59  %:  من  20.1  إلى 
61.1)  ومولودين  حيين  على  الأقل  في  السابق  (في  مقابل  عدم 
إنجاب  مولود؛  نسبة  الانتشار  المصححة:  22.1؛  فاصل  الثقة 
59 %: من 11.1 إلى 53.1) وتشخيص الإصابة بعدوى فيروس 
العوز المناعي البشري أثناء الثلاثة شهور الأولى أو الثانية (في مقابل 
قبل الحمل؛ نسبة الانتشار المصححة: 11.1؛ فاصل الثقة 59 %: 
من 30.1 إلى 02.1). وكان المعدل الإجمالي لانتقال الفيروس من 
الأم  إلى  الطفل  1.4  %  (59  %  فاصل  الثقة:  من  4.3  إلى  9.4)؛ 
وكانت  نسبة  24  %  (94/611)  من  حالات  الانتقال  ناجمة  عن 
8  %  (العدد  =  832)  من  السيدات  اللاتي  لم  تحصلن  على  العلاج 
بمضادات  الفيروسات  القهقرية  قبل  ال�ولادة.  وكان  العلاج 
التوليفي بمضادات الفيروسات القهقرية، مقارنة بالعلاج أحادي 
الدواء  بالزيدوفودين،  مرتبطًا  بزيادة  الانخفاض  بنسبة  07 % 
في  مخاطر  انتقال  الفيروس  من  الأم  إلى  الطفل  (نسبة  الاحتمال 
المصححة: 03.0؛ فاصل الثقة 59 %: من 61.0 إلى 65.0).
الاستنتاج  في  الفترة  من  8002  إلى  0102،  تحسن  الوصول  إلى 
العلاج  التوليفي  بمضادات  الفيروسات  القهقرية  قبل  الولادة 
بشكل  كبير في  أوكرانيا، غير  أن  تنفيذ سياسة  الخيار  ”ب“ لمنظمة 
الصحة العالمية كان بطيئًا. وثمة حاجة ماسة لإجراء تحسينات على 
استبقاء  السيدات  في  رعاية  فيروس  العوز  المناعي  البشري  وزيادة 
نشر الخيار  ”ب“ من أجل التخلص من  انتقال الفيروس من الأم 
إلى الطفل في أوكرانيا.
要摘
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Résultats La part du TPAA a considérablement augmenté, passant 
de 22% des traitements en 2008 à 61% en 2010. Après ajustement 
pour les facteurs confondants possibles, le TZM prénatal, plutôt que 
le TPAA, a été associé au cas de cohabitation (par rapport au mariage; 
ratio de prévalence ajusté, RPa: 1,09; intervalle de confiance (IC) à 
95%: 1,02 à 1,16), à au moins deux naissances antérieures (par rapport 
à aucune; RPa: 1,22; IC à 95%: 1,11 à 1,35) et à un diagnostic d’infection 
au VIH au cours du premier ou du deuxième trimestre (par rapport 
à avant la grossesse; RPa: 1,11; IC à 95%: 1,03 à 1,20). Le taux de TME 
global était de 4,1% (IC à 95%: 3,4 à 4,9), 42% (49/116) des transmissions 
provenaient des 8% (n = 238) de femmes n’ayant pas reçu de TPAA. Par 
rapport au TZM, le TPAA a été associé à une réduction supérieure à 70% 
du risque de transmission mère-enfant (rapport des cotes ajusté, RCa: 
0,3; IC à 95%: 0,16 à 0,56).
Conclusion Entre 2008 et 2010, l’accès au TPAA s’est nettement amélioré 
en Ukraine, mais la mise en œuvre de l’option B de la politique de 
l’Organisation mondiale de la Santé a été lente. Pour que la TME soit 
éliminée en Ukraine, l’amélioration de la rétention des femmes dans 
les services de soins du VIH et la poursuite du déploiement de l’option 
B sont des points urgents à régler.
Резюме
Влияние расширения доступа к комбинированной антиретровирусной терапии во время 
беременности: результаты когортного исследования на Украине
Цель Проведение исследования в области увеличения масштабов 
применения дородовой комбинированной антиретровирусной 
терапии (кАРТ) на Украине с того момента, как она стала частью 
национальной политики в области профилактики передачи от 
матери к ребенку (ППМР) вируса иммунодефицита человека 
(ВИЧ).
Методы Были проанализированы данные по 3535 ВИЧ-
инфицированным беременным женщинам, которые приняли 
участие в Украинско-Европейском совместном исследовании 
в 2008-2010 годах. Были исследованы факторы, связанные с 
использованием монотерапии зидовудином (АЗТм), вместо кАРТ, 
и количеством случаев передачи ВИЧ от матери к ребенку (ПМР).
Результаты Охват терапией кАРТ существенно вырос с 22% 
рождений в 2008 году до 61% в 2010 году. После поправки на 
возможные искажающие факторы, использование дородовой 
АЗТм, вместо кАРТ, было связано с сожительством (по сравнению с 
браком; скорректированный коэффициент распространенности 
(СКР): 1,09; 95% доверительный интервал (ДИ): 1,02-1,16), по 
крайней мере с двумя предыдущими живорождениями (по 
сравнению с их отсутствием; СКР: 1,22, 95% ДИ: 1,11-1,35) и 
постановкой диагноза ВИЧ-инфекции в течение первого 
или второго триместра (по сравнению с его постановкой до 
беременности, СКР: 1,11, 95% ДИ: 1,03-1,20). Общая частота 
ПМР составила 4,1% (95% ДИ: 3,4-4,9), 42% (49/116) случаев 
передачи были у 8% (N = 238) женщин без дородовой АРТ. По 
сравнению с АЗТм, кАРТ привела к 70%-му снижению риска 
ПМР (скорректированное соотношение шансов: 0,30, 95% ДИ: 
0,16-0,56).
Вывод Между 2008 и 2010 годами доступ к дородовой кАРТ на 
Украине существенно улучшился, но реализация проводимой 
Всемирной организацией здравоохранения политики “Вариант 
Б” была слишком медленной. Для полного устранения ПМР на 
Украине требуется расширение участия женщин в программах 
лечения ВИЧ-инфекции и дальнейшее проведение в жизнь 
политики “Вариант Б”.
Resumen
Repercusión del mayor acceso al tratamiento antirretroviral combinado durante el embarazo: resultados de un estudio de 
cohorte en Ucrania
Objetivo Investigar la generalización del tratamiento antirretroviral 
combinado prenatal en Ucrania desde que entró a formar parte de la 
política nacional de prevención de la transmisión de madre a hijo del 
virus de la inmunodeficiencia humana (VIH).
Métodos Se analizaron los datos de 3535 mujeres embarazadas 
seropositivas incluidas en el Estudio Colaborativo Europeo Ucraniano 
entre 2008 y 2010. Se investigaron los factores asociados a la recepción 
de una monoterapia con zidovudina —y no el tratamiento antirretroviral 
combinado prenatal— y las tasas de transmisión de madre a hijo del VIH.
Resultados La cobertura del tratamiento antirretroviral combinado 
prenatal aumentó significativamente, del 22% de partos en 2008 
al 61% de los de 2010. Tras ajustarla por los posibles factores de 
confusión, el inicio de la monoterapia con zidovudina —y no el 
tratamiento antirretroviral combinado prenatal— estuvo asociado 
con la cohabitación (frente a los matrimonios; razón de prevalencia 
ajustada: 1,09; intervalo de confianza 95%: 1,02–1,16), al menos dos 
nacimientos vivos anteriores (frente a ninguno; razón de prevalencia 
ajustada: 1,22; intervalo de confianza 95%: 1,11–1,35) y un diagnóstico 
de infección por VIH durante el primer o segundo trimestre (frente a 
antes del embarazo, razón de prevalencia ajustada: 1,11; intervalo de 
confianza 95%: 1,03–1,20). La tasa total de transmisión de madre a hijo 
fue del 4,1% (intervalo de confianza 95% 3,4–4,9); el 42% (49/116) de las 
transmisiones fueron del 8% (n = 238) de las mujeres que no recibieron 
antirretrovirales prenatales. En comparación con la monoterapia con 
zidovudina, el tratamiento antirretroviral combinado prenatal estuvo 
asociado con una reducción un 70% mayor del riesgo de transmisión 
(razón de posibilidades ajustada: 0,30; intervalo de confianza 95%: 
0,16–0,56).
Conclusión Entre 2008 y 2010, el acceso al tratamiento antirretroviral 
combinado prenatal mejoró sustancialmente en Ucrania, pero la 
implementación del enfoque en la opción B de la Organización Mundial 
de la Salud se reveló lenta. Para eliminar la transmisión de madre a hijo 
en Ucrania, se necesitan con urgencia mejoras en la retención de las 
mujeres en la atención al VIH y un mayor despliegue de la opción B.
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